ES2160688T3 - Procedimiento para obtener una preparacion de clodronato. - Google Patents

Procedimiento para obtener una preparacion de clodronato.

Info

Publication number
ES2160688T3
ES2160688T3 ES95900155T ES95900155T ES2160688T3 ES 2160688 T3 ES2160688 T3 ES 2160688T3 ES 95900155 T ES95900155 T ES 95900155T ES 95900155 T ES95900155 T ES 95900155T ES 2160688 T3 ES2160688 T3 ES 2160688T3
Authority
ES
Spain
Prior art keywords
clodronate
disodic
tetrahydrate
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900155T
Other languages
English (en)
Inventor
Esko Pohjala
Heikki Nupponen
Kari Lehmussaari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Oy
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Application granted granted Critical
Publication of ES2160688T3 publication Critical patent/ES2160688T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ceramic Products (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Glass Compositions (AREA)
  • Seasonings (AREA)
  • Glanulating (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

EL FIN DE LA INVENCION ES UN PROCEDIMIENTO PARA PREPARAR UNA PREPARACION DE CLODRONATO CUYO PROCEDIMIENTO SE CARACTERIZA PORQUE EL CLODRONATO SE CRISTALIZA A MODO DE TETRAHIDRATO DE CLODRONATO DISODICO A PARTIR DE UNA SOLUCION ACUOSA DE CLODRONATO DISODICO; EL TETRAHIDRATO DE CLODRONATO DISODICO RESULTANTE SE GRANULA EN SECO A BASE DE COMPRIMIRLO DE TAL MODO QUE SE MANTENGA LA ESTRUCTURA CRISTALINA DEL TETRAHIDRATO DE CLODRONATO DISODICO Y DE DESMENUZAR Y SEPARAR LA MASA HASTA OBTENER GRANULOS DE TAMAÑO ADECUADO; EL TETRAHIDRATO DE CLODRONATO DISODICO GRANULADO EN SECO SE MEZCLA OPCIONALMENTE CON EXCIPIENTES ADECUADOS, TALES COMO AGENTES DE RELLENO Y AGENTES DE PLANEO Y, EN CASO NECESARIO, DESINTEGRANTES.
ES95900155T 1993-11-12 1994-11-11 Procedimiento para obtener una preparacion de clodronato. Expired - Lifetime ES2160688T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI935019A FI94926C (fi) 1993-11-12 1993-11-12 Menetelmä klodronaattivalmisteen valmistamiseksi

Publications (1)

Publication Number Publication Date
ES2160688T3 true ES2160688T3 (es) 2001-11-16

Family

ID=8538945

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900155T Expired - Lifetime ES2160688T3 (es) 1993-11-12 1994-11-11 Procedimiento para obtener una preparacion de clodronato.

Country Status (25)

Country Link
US (1) US5776499A (es)
EP (1) EP0727983B1 (es)
JP (1) JPH09504800A (es)
KR (1) KR100352155B1 (es)
CN (1) CN1040945C (es)
AT (1) ATE202700T1 (es)
AU (1) AU679586B2 (es)
CA (1) CA2175994A1 (es)
CZ (1) CZ286132B6 (es)
DE (1) DE69427648T2 (es)
DK (1) DK0727983T3 (es)
ES (1) ES2160688T3 (es)
FI (1) FI94926C (es)
GR (1) GR3036470T3 (es)
HU (1) HU220633B1 (es)
IL (1) IL111596A (es)
NO (1) NO312938B1 (es)
NZ (1) NZ275833A (es)
PL (1) PL176658B1 (es)
PT (1) PT727983E (es)
RU (1) RU2141323C1 (es)
SK (1) SK280552B6 (es)
TW (1) TW436297B (es)
WO (1) WO1995013054A1 (es)
ZA (1) ZA948974B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE19808634A1 (de) * 1998-02-24 1999-08-26 Schering Ag Mantel für eine pharmazeutische Zusammensetzung
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
RO121891B1 (ro) 2001-07-04 2008-07-30 Sindan S.R.L. Compoziţie farmaceutică pentru profilaxia şi tratamentul dereglărilor metabolismului calciului şi procedeu de preparare
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
CA3009962C (en) * 2015-12-22 2021-11-09 Stock Company "Chepetsky Mechanical Plant" (Sc Cmp) A method of manufacturing rods from titanium alloys
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
TWI806467B (zh) 2022-03-03 2023-06-21 金兆豐數位科技股份有限公司 金融商品提昇報酬率多維度決策方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
AU687744B2 (en) * 1993-05-15 1998-03-05 Riemser Arzneimittel Ag More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent

Also Published As

Publication number Publication date
DE69427648D1 (de) 2001-08-09
ZA948974B (en) 1995-11-21
RU2141323C1 (ru) 1999-11-20
KR960705548A (ko) 1996-11-08
CN1134664A (zh) 1996-10-30
HU220633B1 (hu) 2002-03-28
CN1040945C (zh) 1998-12-02
EP0727983B1 (en) 2001-07-04
IL111596A0 (en) 1995-01-24
AU679586B2 (en) 1997-07-03
NO312938B1 (no) 2002-07-22
GR3036470T3 (en) 2001-11-30
CZ286132B6 (cs) 2000-01-12
WO1995013054A1 (en) 1995-05-18
PL314299A1 (en) 1996-09-02
AU8108794A (en) 1995-05-29
KR100352155B1 (ko) 2002-12-31
FI94926B (fi) 1995-08-15
IL111596A (en) 1998-12-06
HU9601257D0 (en) 1996-07-29
JPH09504800A (ja) 1997-05-13
PT727983E (pt) 2001-11-30
CA2175994A1 (en) 1995-05-18
NO961906D0 (no) 1996-05-10
DE69427648T2 (de) 2002-04-18
FI94926C (fi) 1995-11-27
FI935019A0 (fi) 1993-11-12
HUT75228A (en) 1997-04-28
FI935019A (fi) 1995-05-13
ATE202700T1 (de) 2001-07-15
DK0727983T3 (da) 2001-09-24
CZ132796A3 (en) 1996-10-16
PL176658B1 (pl) 1999-07-30
EP0727983A1 (en) 1996-08-28
SK60696A3 (en) 1997-02-05
TW436297B (en) 2001-05-28
NZ275833A (en) 1997-10-24
US5776499A (en) 1998-07-07
NO961906L (no) 1996-05-23
SK280552B6 (sk) 2000-03-13

Similar Documents

Publication Publication Date Title
ES2160688T3 (es) Procedimiento para obtener una preparacion de clodronato.
ES2529167T3 (es) Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares
ES2040321T3 (es) Procedimiento para la preparacion de acido folinico.
ES2058951T3 (es) Procedimiento para la produccion de actinio-225 y bismuto-213.
AR041831A1 (es) Composicion de enlucido para relleno de juntas para elementos de construccion y procedimiento de realizacion de una obra
ES2088973T3 (es) Cloracion mejorada de 6-esteres de sacarosa.
AR059764A2 (es) Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
EA200200951A1 (ru) Фармацевтические композиции
ES2174293T3 (es) Microesferas farmaceuticas de acido valproico para la administracion oral.
ES2080401T3 (es) Procedimiento para la preparacion de copoliesteres estadisticos.
ES2061226T3 (es) Procedimiento para la fabricacion hidrotermica de soluciones de silicato potasico.
ES2045828T3 (es) Metodo para a/adir lecitina a goma de mascar.
ES2062796T3 (es) Procedimiento para producir un mejorador de detergencia aglomerado de 2,2'-oxodisuccinato y zeolita a.
JPS52110563A (en) Hexagonal boride cathode
JPS52143217A (en) Stable composition containing prostaglandi ne
ES2162324T3 (es) Procedimiento de secado por pulverizacion para producir composiciones detergentes que implican premezclar polimeros de poliaminas modificadas.
ES2119450T3 (es) Procedimiento para la obtencion de perlas y perlas obtenidas que contienen un principio activo que presenta un punto de fusion no definido.
ES529062A0 (es) Un procedimiento para la produccion de una mezcla de sulfosuccionatos de dialquilo activa como detergente
DE69914327D1 (de) Biologisch aktive mikrodispersionszusammensetzung
ES2055213T3 (es) Procedimiento para la obtencion de poliisocianatos.
AR004490A1 (es) Procedimiento para preparar compuestos biocidas de liberacion sostenida.
ES2138423T3 (es) Procedimiento para la obtencion de polimeros sindiotacticos y parcialmente cristalinos a partir de monomeros vinilaromaticos.
JPS5430102A (en) Carbon-carbon bond formation
ES2195925T3 (es) Proceso para fabricar una formulacion de liberacion retardada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 727983

Country of ref document: ES